Ceritinib-platinum (IV) -4-phenylbutyrate
Ceritinib-platinum (IV) -4-phenylbutyrate (complex 7) is a Ceritinib -conjugated Platinum (IV) prodrug with anticancer activity. Ceritinib-platinum (IV) -4-phenylbutyrate induces S-phase arrest, DNA damage responses, and apoptosis. Ceritinib-platinum (IV) -4-phenylbutyrate combines cytotoxicity with immune and anti-invasive activation in cancer cell models. Ceritinib-platinum (IV) -4-phenylbutyrate can be used for cancer research, such as non-small cell lung cancer (NSCLC).
Product Specifications
UNSPSC
12352005
Target
Apoptosis
Related Pathways
Apoptosis
Field of Research
Cancer
Smiles
CC1=CC(NC2=NC=C(C(NC3=CC=CC=C3S(=O)(C(C)C)=O)=N2)Cl)=C(C=C1C4CCN(CC4)C(O[Pt]([NH3])(Cl)([NH3])(OC(CCCC5=CC=CC=C5)=O)Cl)=O)OC(C)C
Molecular Formula
C39H52Cl3N7O7PtS
Molecular Weight
1064.38
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
TNF alpha (J2D10), CF568 conjugate, 0.1mg/mL
Ep-CAM / CD326 (Epithelial Marker) (rVU-1D9), CF405S conjugate, 0.1mg/mL
CD45RO (190-2F2.5), CF647 conjugate, 0.1mg/mL
